Leap's DKK1 antibody plus BeiGene's PD-1 drug show promise for gastric cancer; Eluminex Bio, CTTQ, Neurophth - News of the day
Elise Mak · 01/21/2022
Leap Therapeutics' anti-DKK1 antibody in combination with BeiGene's anti-PD-1 antibody demonstrated clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients. More news from Eluminex Bio, CTTQ, Neurophth, BeiGene and the CDE.
Innovent licenses three enzyme-specific inhibitors from Amagma for inflammatory diseases; Pharbers, BioTroy, Biocytogen - News of the day
Elise Mak · 01/20/2022
Innovent Biologics is licensing the Greater China rights to up to three enzyme-specific inhibitors from Amagma Therapeutics to strengthen its inflammatory disease portfolio. More news from Pharbers, BioTroy, Biocytogen, Neukio and Hengrui Pharma.
Mabwell debuts on STAR with $547M IPO; BeiGene, Huaota - News of the day
Elise Mak · 01/19/2022
Mabwell is the 13th pre-revenue biotech startup listed on STAR. It raised RMB3.477 billion ($547 million) with an offer price of RMB34.8 apiece. It opened at RMB32 then further dropped to RMB24.5 to end the day.
Abbisko partners with Eli Lilly to develop novel molecules for cardiometabolic diseases; ReviR Therapeutics, Leman, SparX Bio - News of the day
Elise Mak · 01/18/2022
Abbisko Therapeutics has inked a pact with Eli Lilly to develop and commercialise novel molecules against an undisclosed target for cardiometabolic diseases. More news from ReviR Therapeutics, Leman and SparX Bio.
CStone's PD-L1 drug improves progression-free survival as first-line treatment of stage IV NSCLC; Junsai, Gracell, BeyondSpring - News of the day
Elise Mak · 01/17/2022
CStone's study provides the only anti-PD-L1 immunotherapy plus chemotherapy option for squamous NSCLC patients worldwide. More news from Junsai, Gracell, BeyondSpring, HISUN, EastChina, Shenogen and Betta.
Everest gains global rights to oral COVID-19 drugs; REC Bio - News of the day
Elise Mak · 01/14/2022
After securing COVID-19 vaccines from Providence Therapeutics, Everest Medicines now gets hold of oral drugs for the coronavirus to shore up its COVID portfolio. More news from REC Bio.
Vibrant Therapeutics closes Series pre-A for AI-driven large molecule drug development; Smart Nuclide, Hober Biotech, CStone - News of the day
Elise Mak · 01/13/2022
Vibrant Therapeutics, a Guangzhou-based startup founded in 2019, closed a Series pre-A round to raise RMB100 million ($15.7 million) to accelerate AI-driven large molecule drug development. More news from Smart Nuclide, Hober Biotech, CStone and the CDE.
Junshi licenses out TIGIT program to Coherus in expanded deal; Sana, Innovent, Fosun - News of the day
Elise Mak · 01/12/2022
Coherus and Junshi Biosciences are planning late-stage clinical development of TIGIT-targeted antibody JS006 in combination with toripalimab in North America, and more news from Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics, Fosun Pharma and Insilico Medicine, Kexing Biopharm, Yizun Biomedical, Echo Biotec, Kyowa Kirin, Hisun Pharmaceutical, Betta Pharma, Hengrui Pharma and the ...
New cell therapy startup Binhu Biotech raises nearly $31.3M; Xellsmart, Youcare, BeiGene - News of the day
Elise Mak · 01/11/2022
Incubated by Legend Capital, Binhu Biotech said it has raised nearly RMB200 million to develop universal cell and gene therapies for oncology, autoimmune diseases, and genetic diseases, and more news from Xellsmart, Youcare, BeiGene, CANbridge, Eli Lilly, JW Therapeutics and Chinese regulators.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement